BIVALIRUDIN
| Brand name | ANGIOMAX |
|---|---|
| Active ingredient | BIVALIRUDIN |
| Strength | 250MG/VIAL |
| Dosage form | INJECTABLE |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | December 2000 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 7582727*PED | January 2029 | — |
| 7598343*PED | January 2029 | — |
| 7582727 | July 2028 | product |
| 7598343 | July 2028 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.